Navigation Links
Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
Date:8/15/2012

IRVINE, Calif., Aug. 15, 2012 /PRNewswire/ -- Antigen Discovery Inc. (ADi) today announced that it has received a Phase I Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The two-year $600,000 award will fund a collaborative research effort between ADi and the Henry Samueli School of Engineering at University of California, Irvine (UCI) to develop a fully integrated microfluidic immunodiagnostic platform.  Threats from infectious disease have been growing at an alarming pace worldwide; there is a critical need for accurate, rapid, and readily deployable diagnostics during mass disasters, natural disease outbreaks, and bioterrorist threats.  This joint effort will take advantage of a novel air-liquid cavity acoustic transducer (ALCAT) technology pioneered by Dr. Abraham Lee's group at UCI, and ADi's protein microarray technology and large library of serodiagnostic antigens from dozens of infectious disease targets.  Dr. Xiaowu Liang, President and CEO of ADi, states that "the development of hand-held point-of-care (POC) diagnostics will meet a vital need as the portability, ease-of-use, and prompt sample-to-answer times allow first responders to effectively assess the prevalence and spread of exposure in a population during major outbreaks."  

"We will design and build a microfluidic polymer-based chip that utilizes ALCAT which provides the fluid actuation required for complex reagent handling in multi-step colorimetric immunoassays," added Dr. Abraham Lee, Principle Investigator, Chair of the Department of Biomedical Engineering and Director of the Micro/nano Fluidics Fundamentals Focus (MF3) Center at UCI. "ALCAT's versatility as a single actuation technology is an easier method for on-chip integration compared to other POC platforms that require a different actuator for each fluidic process. By incorporating novel ALCAT-based approaches into protein microarray assays, we will have the versatility and power to reduce enzymatic development times, limit production costs, and fully integrate all components into a disposable assay."

While ADi has received a number of SBIR/STTR awards in the past, this is the first time the company has received a grant for development of a medical device. "Thanks to support from the NIAID, we have been able to build a significant portfolio of diagnostic markers for a wide range of infectious agents," said Dr. Philip Felgner, Founder and Chairman of ADi. "We now plan to develop a point-of-care diagnostic system consisting of a cost-effective disposable microfluidic plastic chip and a portable analyzer that can be driven by a mobile computing device such as a smart phone for rapid serological evaluation of exposure and infections."

About Antigen Discovery Inc.
Antigen Discovery Inc. is a privately owned biotechnology company located in Irvine, California. ADi has a proprietary high throughput proteomics platform technology for biomarker discovery. The company uses and commercializes its innovative proteome microarrays and testing models to facilitate the development of new diagnostic tests, therapeutics and vaccines for infectious disease, autoimmunity, cancer and more. For more information about ADi, see http://www.antigendiscovery.com.

Contact:

Angela Yee
ayee@antigendiscovery.com


'/>"/>
SOURCE Antigen Discovery Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
3. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
4. Generex Augments Antigen Express Scientific Advisory Board
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
7. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
8. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
11. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/1/2017)... , Sept. 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ... greatest aural experiences — and deliver these experiences as part ... help people feel and heal better. ... While nothing beats a walk, jog ... your mind, Life Environments™ is the next best thing when ...
Breaking Medicine Technology:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance ... research, education and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. ... Sellati has more than 20 years of research experience with Lyme and other ...
(Date:9/21/2017)... ... 21, 2017 , ... The American Addiction Treatment Association (AATA) ... in the addiction treatment industry entitled: Special Investigations Unit (SIU) – What ... state and federal governments are increasingly scrutinizing the addiction treatment industry for fraudulent ...
(Date:9/21/2017)... ... , ... In addition to sticking with the new years ... and use natural alternatives for all house cleaning products, disinfectants, respiratory relief, and ... the new line of essential oils, are all 100% organic and natural. , ...
(Date:9/21/2017)... RICHMOND, Va. (PRWEB) , ... September 21, 2017 ... ... Richmond with a different approach to addiction recovery at a time when Virginia ... 1,420 deaths resulting from drug overdose, a staggering increase of 38 percent from ...
Breaking Medicine News(10 mins):